BeOne Medicines (BEIGF) Receivables (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Receivables data on file, last reported at $938.0 million in Q1 2026.

• Receivables for Q1 2026 came in at $938.0 million, up 30.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $938.0 million (up 30.78% YoY), and the FY2025 annual result was $865.1 million, up 27.92% from the prior year.
• Receivables improved to $938.0 million in Q1 2026 per BEIGF's latest filing, from $865.1 million in the prior quarter.
• Over five years, Receivables peaked at $938.0 million in Q1 2026 and troughed at $174.9 million in Q2 2022.
• A 5-year average of $493.3 million and a median of $435.3 million in 2024 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 125.44% in 2022 and fell as far as 63.9% in 2022.
• A 5-year view of Receivables shows it stood at $176.2 million in 2022, then surged by 104.17% to $359.8 million in 2023, then jumped by 87.98% to $676.3 million in 2024, then climbed by 27.92% to $865.1 million in 2025, then gained by 8.43% to $938.0 million in 2026.
• Business Quant data shows BEIGF's Receivables at $938.0 million in Q1 2026, $865.1 million in Q4 2025, and $863.3 million in Q3 2025.